Fibrinolysis is amplified by converting α2-antiplasmin from a plasmin inhibitor to a substrate

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2087-2094

  Sazonova, I Y ^a   Thomas, B M ^a   Gladysheva, I P ^a   Houng, A K ^a   Reed, Guy L ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Cardiovascular Research Center   (United States)

Author keywords

Antiplasmin; Fibrinolysis; Inhibition; Plasminogen activation

Indexed keywords

ALPHA 2 ANTIPLASMIN; EPITOPE; FIBRIN; LYSINE; MICROPLASMIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 49; MONOCLONAL ANTIBODY 77; MONOCLONAL ANTIBODY RWR; PLASMIN; PLASMIN INHIBITOR; SERINE PROTEINASE INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME SUBSTRATE; FIBRINOLYSIS; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN PROTEIN INTERACTION; STOICHIOMETRY;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIPLASMIN; EPITOPES; FIBRINOLYSIS; HUMANS; MOLECULAR SEQUENCE DATA; PLASMIN; PLASMINOGEN; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 34548829907     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02652.x     Document Type: Article

References (29)

1. Leys D. Atherothrombosis: A major health burden. Cerebrovasc Dis 2001; 11: 1-4.
2. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-24.
3. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activator inhibitor-1: Physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002; 42: 1187-99.
4. Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Cross-linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275: 37382-9.
5. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-8.
6. van Giezen JJ, Minkema J, Bouma BN, Jansen JW. Cross-linking of alpha 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: species differences. Blood Coagul Fibrinolysis 1993; 4: 869-75.
7. Butte AN, Houng AK, Jang IK, Reed GL. Alpha 2-antiplasmin causes thrombi to resist fibrinolysis induced by tissue plasminogen activator in experimental pulmonary embolism. Circulation 1997; 95: 1886-91.
8. Nagai N, De Mol M, Van Hoef B, Verstreken M, Collen D. (2001) Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization. Blood 2001; 97: 3086-92.
9. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987a; 262: 1659-64.
10. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
11. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-8.
12. Schechter NM, Plotnick MI. Measurement of the kinetic parameters mediating protease-serpin inhibition. Methods 2004; 32: 159-68.
13. Edy J, Collen D. The interaction in human plasma of antiplasmin, the fast-reacting plasmin inhibitor, with plasmin, thrombin, trypsin and chymotrypsin. Biochim Biophys Acta 1977; 484: 423-32.
14. Reed GLd, Matsueda GR, Haber E. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin. Trans Assoc Am Physicians 1988; 101: 250-6.
15. Reed GL. Functional characterization of monoclonal antibody inhibitors of alpha 2-antiplasmin that accelerate fibrinolysis in different animal plasmas. Hybridoma 1997; 16: 281-6.
16. Reed GL, Houng AK, Liu L, Parhami-Seren B, Matsueda LH, Wang S, Hedstrom L. A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc Natl Acad. Sci USA 1999; 96: 8879-83.
17. Turner RB, Liu L, Sazonova IY, Reed GL. Structural Elements that Govern the Substrate Specificity of the Clot Dissolving Enzyme Plasmin. J Biol Chem 2002; 277: 33068-74.
18. Reed GL, Matsueda GR, Haber E. Platelet factor XIII increases the fibrinolytic resistance of platelet-rich clots by accelerating the crosslinking of alpha 2-antiplasmin to fibrin. Thromb Haemost 1992; 68: 315-20.
19. Lukacova D, Matsueda GR, Haber E, Reed GL. Inhibition of Factor XIII activation by an anti-peptide monoclonal antibody. Biochemistry 1991; 30: 10164-70.
20. Rijken DC, Groeneveld E, Kluft C, Nieuwenhuis HK. Alpha 2-antiplasmin Enschede is not an inhibitor, but a substrate, of plasmin. Biochem J 1988; 255: 609-15.
21. Frank PS, Douglas JT, Locher M, Llinas M, Schaller J. Structural/ functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide. Biochemistry 2003; 42: 1078-85.
22. Koyama T, Koike Y, Toyota S, Miyagi F, Suzuki N, Aoki N. Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
23. Holmes W, Lijnen H, Nelles L, Kluft C, Nieuwenhuis H, Rijken D, Collen D. Alpha 2-antiplasmin Enschede: Alanine insertion and abolition of plasmin inhibitory activity. Science 1987b; 238: 209-11.
24. Reed GLd, Matsueda GR, Haber E. Synergistic fibrinolysis: Combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin. Proc Natl Acad Sci USA 1990a; 87: 1114-8.
25. Verhamme I, Kvassman JO, Day DE, Debrock S, Vleugels N, Declerck PJ, Shore JD. Accelerated conversion of human plasminogen activator inhibitor-1 to its latent form by antibody binding. J Biol Chem 1999; 274: 17511-7.
26. Bijnens AP, Gils A, Stassen JM, Komissarov AA, Knockaert I, Brouwers E, Shore JD, Declerck PJ. The distal hinge of the reactive site loop and its proximity: A target to modulate plasminogen activator inhibitor-1 activity. J Biol Chem 2001; 276: 44912-8.
27. Komissarov AA, Declerck PJ, Shore JD. Mechanisms of conversion of plasminogen activator inhibitor 1 from a suicide inhibitor to a substrate by monoclonal antibodies. J Biol Chem 2002; 277: 43858-65.
28. Ngo TH, Hoylaerts MF, Knockaert I, Brouwers E, Declerck PJ. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties. J Biol Chem 2001; 276: 26243-8.
29. Reed GLd, Matsueda GR, Haber E. Inhibition of clot-bound alpha 2-antiplasmin enhances in vivo thrombolysis. Circulation 1990b; 82: 164-8.